Results 161 to 170 of about 66,786 (240)

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source

Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A combination of nucleotide hepatitis C virus (HCV) nonstructural protein (NS) 5B and 5A inhibitors is a preferred standard of care for treating chronic HCV. Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against HCV NS5B.
Xiao‐Jian Zhou, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond   +7 more
wiley   +1 more source

Advances in Isotope Labeling for Solution Nucleic Acid Nuclear Magnetic Resonance Spectroscopy

ChemPlusChem, EarlyView.
Recent advances in the field of nucleic acid nuclear magnetic resonance (NMR) are presented. Stable isotope labeling protocols and new approaches to segmentally label nucleic acid with NMR‐active residues are summarized. The novel methods will have a strong impact on the future of nucleic acid NMR and the characterization of structure and dynamics of ...
Stefan Hilber, Solomon Kojo Attionu, Theodore Kwaku Dayie, Christoph Kreutz   +3 more
wiley   +1 more source

Night‐Time Chronotherapy with Methylprednisolone Prevents an Acute Rejection in Pediatric Patients with Liver Transplantation: A Randomized Clinical Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Concept of methylprednisolone chronotherapy to prevent acute rejections. While endogenous cortisol secretion rises in the early morning, the number of lymphocytes in the blood is higher at night, thus exhibiting an antiphase pattern to cortisol secretion. Therefore, compared with the daytime, the infiltration of lymphocytes into immune‐reactive tissues
Kentaro Ushijima, Yukihiro Sanada, Shinya Otomo, Keiko Ogaki, Taiichi Wakiya, Noriki Okada, Yuta Hirata, Yasuharu Onishi, Yasunaru Sakuma, Yukiyo Wada, Akio Fujimura, Koichi Mizuta   +11 more
wiley   +1 more source

Populations Addressed in Vaccines Approved via the European Medicines Agency

Clinical Pharmacology &Therapeutics, EarlyView.
Therapeutic and prophylactic agents require robust evidence before patient use. Randomized controlled trials are essential for evaluating safety and efficacy but often exclude specific populations that are also targets for the intervention. This study assessed which populations are included in vaccine registration studies and/or addressed in label ...
Débora D. Gräf, Lukas Westphal, Jonathan Kimmelman, Christine E. Hallgreen   +3 more
wiley   +1 more source

Rethinking Chlorine: Essential Chemical or Replaceable Risk?

ChemSusChem, EarlyView.
Chlorine is essential for the production of plastics and pharmaceuticals but poses significant safety and environmental risks. Herein, processes are presented that substitute chlorine or reduce its demand. Where indispensable, trichloride‐ and bichloride‐based ionic liquids could enhance safety and streamline the integration of renewable energy ...
Johannes Schwan, Merlin Kleoff, Gesa H. Dreyhsig, Patrick Voßnacker, Traute Fiedler, Marian Rosental, Sebastian Riedel   +6 more
wiley   +1 more source

OMIP‐114: A 36‐Color Spectral Flow Cytometry Panel for Detailed Analysis of T Cell Activation and Regulation in Small Human Blood Volumes

Cytometry Part A, EarlyView.
ABSTRACT This 36‐color flow cytometry panel is designed to characterize multiple lymphocyte compartments, with a focus on T cells, their memory subpopulations, and immune checkpoints in human whole blood samples. In clinical settings, the amount of blood available from patients for scientific research is often limited.
Marie‐Theres Thieme‐Ehlert, Thomas Jacobs, Johannes Brandi, Maria Sophia Mackroth   +3 more
wiley   +1 more source

Differentiating reactive and neoplastic gamma‐delta (γδ) T‐cell expansions in the peripheral blood and bone marrow

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract The clinical and immunophenotypic attributes of reactive γδ T‐cell expansions are less well characterized than their malignant counterparts, which can pose diagnostic challenges. This study aims to investigate the characteristics and long‐term clinical outcomes of reactive γδ T‐cell expansions.
Hamza Tariq, Zubair Ilyas, Lucy Fu, Yijie Liu, Qing Ching Chen, Kristy Wolniak, Yi‐Hua Chen   +6 more
wiley   +1 more source

Discovering new hub genes of dilated cardiomyopathy

ESC Heart Failure, EarlyView.
Abstract Aims Dilated cardiomyopathy (DCM) has a poor prognosis and exhibits a complex and diverse aetiology and genetic profile. The genes responsible for the pathogenesis of DCM have not been fully identified. The present study aimed to explore new hub genes of DCM by mining the human DCM databases and further by experimental validation.
Jun‐Yan Zhu, Yu Han, Jing‐Yu Yang, De‐Ping Wang, Li‐Juan Gao, Teng Sun, Yan‐Lin Feng, Zhong‐Mei He, Bin Zhou, Ji‐Min Cao   +9 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events

ESC Heart Failure, EarlyView.
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna, Elia Rigamonti, Raffaele Zannoni, Vittoria Espeli, Giorgio Moschovitis   +4 more
wiley   +1 more source